| 000 | 01708 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516191434.0 | ||
| 264 | 0 | _c20150515 | |
| 008 | 201505s 0 0 eng d | ||
| 022 | _a1875-5402 | ||
| 024 | 7 |
_a10.2174/1386207317666140109124735 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChung, Thomas D Y | |
| 245 | 0 | 0 |
_aCollaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models. _h[electronic resource] |
| 260 |
_bCombinatorial chemistry & high throughput screening _cMar 2014 |
||
| 300 |
_a272-89 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAcademies and Institutes |
| 650 | 0 | 4 | _aBiotechnology |
| 650 | 0 | 4 |
_aCalcinosis _xdrug therapy |
| 650 | 0 | 4 | _aCalifornia |
| 650 | 0 | 4 | _aChemistry, Pharmaceutical |
| 650 | 0 | 4 | _aComputational Biology |
| 650 | 0 | 4 | _aCooperative Behavior |
| 650 | 0 | 4 |
_aDrug Discovery _xorganization & administration |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aDrug Industry |
| 650 | 0 | 4 | _aGenomics |
| 650 | 0 | 4 | _aHigh-Throughput Screening Assays |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInventions |
| 650 | 0 | 4 | _aNational Institutes of Health (U.S.) |
| 650 | 0 | 4 | _aOrganizational Innovation |
| 650 | 0 | 4 | _aPharmacology |
| 650 | 0 | 4 | _aSoftware |
| 650 | 0 | 4 |
_aTranslational Research, Biomedical _xorganization & administration |
| 650 | 0 | 4 | _aUnited States |
| 773 | 0 |
_tCombinatorial chemistry & high throughput screening _gvol. 17 _gno. 3 _gp. 272-89 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1386207317666140109124735 _zAvailable from publisher's website |
| 999 |
_c23435487 _d23435487 |
||